T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who had been administered the radio contrast media amidotrizoate multiple times without issue but who then devel...
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
BMJ Publishing Group
2021-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Acceso en liña: | https://jitc.bmj.com/content/9/5/e002521.full |